

OXIS International announces Oxis Biotech Inc., Completion of \$2.675 million Financing, Appointment of Chief Financial Officer and Board Member

BEVERLY HILLS, Calif., Nov. 11, 2014 -- Oxis International, Inc. (OXIS) announced today its wholly owned subsidiary, Oxis Biotech, Inc., the completion of an additional round of financing, and the appointment of Steven Weldon as Chief Financial Officer, Chief Accounting Officer and member of the Board of Directors.

Oxis International, Inc. has formed and provided initial financing to support the activities of its wholly owned subsidiary, Oxis Biotech, Inc. The parent company, Oxis International is engaged in the research, development and sale of products to counteract oxidative stress and inflammation. Oxis Biotech is focused on the acquisition of cannabis related intellectual properties and commercialization of therapies developed from the intellectual properties to treat certain diseases. Mr. Tony Cataldo has been named President of Oxis Biotech, Inc.

Oxis International completed an additional round of financing in the amount of US\$1.25 million. An earlier round of financing completed in July of US\$1.425 million, and the most recent financing brings the funding total for 2014 to US\$2.675 million. The use of proceeds include funding for Oxis Biotech, Inc. activities related to the acquisition and/or licensing of cannabis related intellectual properties, marketing of Oxis International, Inc's nutraceutical products, and general corporate purposes.

Mr. Steven Weldon has been appointed Chief Financial Officer, Chief Accounting Officer, and elected a member of the Board of Directors. Mr. Weldon is a certified public accountant licensed to practice in the state of Florida. Mr. Weldon has over 15 years of financial and accounting experience with public and private companies. Mr. Weldon received his Bachelor of Science degree and his Masters in Business Administration from Florida Southern College, where he was an adjunct professor.

Oxis Chairman Tony Cataldo said, "The developments at Oxis Biotech, Inc. gives us the platform and the initial funding we need to be laser focused on cannabis related opportunities. I am very excited to be leading the charge as we identify therapies that could become the help millions of patients around the world have been looking for."

OXIS CEO Kenneth Eaton stated, "The formation and initial funding of Oxis Biotech, Inc., the completion of this round of financing, and the addition of Steven Weldon are all very important to Oxis. As we grow, building the right team of professionals will allow us to take full advantage of business opportunities for our shareholders."

Forward-Looking Statements Except for historical information contained herein, the statements in this release are forward-looking and made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are inherently unreliable and actual results may differ materially. Examples of forward-looking statements in this news release include statements regarding the payment of dividends, marketing and distribution plans, development activities and anticipated operating results. Factors which could cause actual results to differ materially from these forward-looking statements include such factors as the Company's ability to accomplish its business initiatives, significant fluctuations in marketing expenses and ability to achieve and expand significant levels of revenues, or recognize net income, from the sale of its products and services, as well as the introduction of competing products, or management's ability to attract and maintain qualified personnel necessary for the development and commercialization of its planned products, and other information that may be detailed from time to time in the Company's filings with the United States Securities and Exchange Commission. The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Contact:

Jon Barkman
Riverview Capital Enterprises

[866-224-2999](tel:866-224-2999)